2,911 United Therapeutics Corporation $UTHR Shares Sold by Tower View Wealth Management LLC

Tower View Wealth Management LLC trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 96.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 95 shares of the biotechnology company’s stock after selling 2,911 shares during the quarter. Tower View Wealth Management LLC’s holdings in United Therapeutics were worth $51,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in UTHR. Arjuna Capital lifted its stake in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the last quarter. Sage Rhino Capital LLC boosted its holdings in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC grew its position in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. grew its position in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares during the last quarter. Finally, Kera Capital Partners Inc. increased its stake in United Therapeutics by 6.1% in the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 27 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,587,119.60. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $560.07, for a total transaction of $5,320,665.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $181,710,791.01. This trade represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 392,028 shares of company stock valued at $203,299,671 in the last three months. 8.60% of the stock is owned by insiders.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. The Goldman Sachs Group reissued a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a report on Thursday, October 15th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Jefferies Financial Group restated a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 14th. Finally, UBS Group set a $725.00 price objective on shares of United Therapeutics in a research note on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $650.43.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: $2 billion buyback authorization: United Therapeutics’ board approved an additional $2 billion share-repurchase program, potentially covering up to 8.3% of outstanding shares. The authorization could reduce the share count, support future earnings per share and signal that management considers the stock undervalued. United Therapeutics Authorizes Additional $2 Billion Share Buyback Program
• Positive Sentiment: Analyst targets remain above the current share price: Recent research includes bullish ratings and targets as high as $725. The broader analyst consensus remains “Moderate Buy,” with an average target of approximately $650, although ratings are not unanimous. Analysts Conflicted on United Therapeutics
• Neutral Sentiment: CEO sold a relatively small portion of holdings: CEO Martine Rothblatt sold 9,500 shares for about $5.3 million, reducing her direct ownership by 2.84%. She still owns more than 324,000 shares, so the transaction may represent personal diversification rather than a change in business outlook. SEC Insider Trading Filing
• Negative Sentiment: Tyvaso faces near-term pressure: RBC warned that United Therapeutics’ settlement with Liquidia could weigh on the outlook for Tyvaso, raising concerns about competition and growth for the company’s key pulmonary arterial hypertension franchise. United Therapeutics Tyvaso Outlook Faces Near-Term Pressure

United Therapeutics Price Performance

Shares of UTHR stock opened at $587.50 on Monday. The business’s fifty day moving average is $519.14 and its 200 day moving average is $539.93. The stock has a market cap of $25.20 billion, a price-to-earnings ratio of 21.02, a PEG ratio of 4.26 and a beta of 0.49. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the company earned $6.41 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Corporation will post 26.07 earnings per share for the current fiscal year.

United Therapeutics announced that its board has approved a share repurchase program on Thursday, October 22nd that permits the company to buy back $2.00 billion in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.